Innocan Pharma Corporation

Innocan Pharma Corporation is a pharmaceutical technology company focused on developing innovative drug delivery platforms, particularly leveraging cannabinoid science. The company's mission is to unlock the therapeutic potential of cannabinoids through advanced delivery formulas, aiming to provide safe, non-opioid chronic pain management solutions for both human and animal health. Headquartered in Herzliya, Israel, with operations also in Calgary, Alberta, Canada, Innocan Pharma operates across two primary segments: Pharmaceuticals and Consumer Wellness.

In its Pharmaceuticals segment, Innocan Pharma is developing a CBD-loaded liposome drug delivery platform (LPT-CBD) designed for precise dosing and prolonged, controlled release of synthetic CBD. This platform is currently in preclinical trial phases for indications such as epilepsy and pain management. The company also explores a CLX CBD-loaded exosomes platform for neurological and inflammatory diseases and holds patents for topical pain relief technology. The Consumer Wellness segment focuses on developing and marketing a diverse portfolio of high-performance self-care and beauty products, often integrated with CBD, to promote a healthier lifestyle. This segment operates largely through its 60% owned subsidiary, BI Sky Global Ltd., which specializes in advanced online sales channels.

Led by CEO Iris Bincovich, who was appointed in January 2018, Innocan Pharma reported revenues of approximately US$26.6 million for fiscal year 2025. The company has recently received a fee waiver from the FDA Center for Veterinary Medicine for the third consecutive time in 2026 and has demonstrated pain relief with its LPT-CBD in canine clinical studies. Innocan Pharma has expanded its intellectual property portfolio with patent allowances in Japan for its Liposomal CBD Injection Technology and in Mexico for its topical pain relief technology, while actively broadening its IP coverage in Asia. The company is also pursuing a proposed U.S. public offering and has applied to list on the Nasdaq Capital Market under the symbols "INNP" and "INNPW."